Promising breast cancer drug trial halted early
NCT ID NCT06162351
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called PLX038 in 14 people with advanced triple-negative breast cancer that had already been treated. The goal was to see if the drug could shrink tumors. The trial was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Curie
Paris, 75248 Cedex, France
-
Institut Curie
Saint-Cloud, 92210, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?